bbT369

· Regeneron Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for bbT369, covering 2025-10-21 to 2025-10-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1]